DK3886799T3 - Sammensætninger til behandlingen af hårtab - Google Patents

Sammensætninger til behandlingen af hårtab Download PDF

Info

Publication number
DK3886799T3
DK3886799T3 DK20760994.2T DK20760994T DK3886799T3 DK 3886799 T3 DK3886799 T3 DK 3886799T3 DK 20760994 T DK20760994 T DK 20760994T DK 3886799 T3 DK3886799 T3 DK 3886799T3
Authority
DK
Denmark
Prior art keywords
compositions
treatment
hair loss
hair
loss
Prior art date
Application number
DK20760994.2T
Other languages
English (en)
Inventor
John Edward Wurst
Original Assignee
Aneira Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aneira Pharma Inc filed Critical Aneira Pharma Inc
Application granted granted Critical
Publication of DK3886799T3 publication Critical patent/DK3886799T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/591—Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK20760994.2T 2019-08-07 2020-08-03 Sammensætninger til behandlingen af hårtab DK3886799T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962883809P 2019-08-07 2019-08-07
US201962895869P 2019-09-04 2019-09-04
US202063100611P 2020-03-23 2020-03-23
PCT/US2020/044771 WO2021026084A1 (en) 2019-08-07 2020-08-03 Compositions for the treatment of hair loss

Publications (1)

Publication Number Publication Date
DK3886799T3 true DK3886799T3 (da) 2023-12-18

Family

ID=72193579

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20760994.2T DK3886799T3 (da) 2019-08-07 2020-08-03 Sammensætninger til behandlingen af hårtab

Country Status (27)

Country Link
US (11) US10993944B2 (da)
EP (2) EP3886799B1 (da)
JP (1) JP2022543532A (da)
KR (1) KR20220044248A (da)
CN (1) CN114007634A (da)
AU (1) AU2020324403A1 (da)
BR (1) BR112022000229A2 (da)
CA (1) CA3140841A1 (da)
CL (1) CL2022000067A1 (da)
CO (1) CO2022000214A2 (da)
DK (1) DK3886799T3 (da)
EC (1) ECSP22001774A (da)
ES (1) ES2966317T3 (da)
FI (1) FI3886799T3 (da)
HR (1) HRP20231629T1 (da)
HU (1) HUE064366T2 (da)
IL (1) IL289687A (da)
LT (1) LT3886799T (da)
MD (1) MD3886799T2 (da)
MX (2) MX2021014220A (da)
PL (1) PL3886799T3 (da)
PT (1) PT3886799T (da)
RS (1) RS64965B1 (da)
SA (1) SA522431538B1 (da)
SI (1) SI3886799T1 (da)
TW (1) TW202220665A (da)
WO (1) WO2021026084A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10993944B2 (en) * 2019-08-07 2021-05-04 Aneira Pharma, Inc. Methods and compositions for the treatment of hair loss
WO2024205347A1 (ko) * 2023-03-30 2024-10-03 신신제약 주식회사 미녹시딜을 함유하는 탈모 치료용 조성물

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596812A (en) 1976-05-24 1986-06-24 The Upjohn Company Methods and solutions for treating male pattern alopecia
US4139619A (en) 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
LU86548A1 (fr) 1986-08-07 1988-03-02 Oreal Composition sous forme de gel pour induire et stimuler la croissance des cheveux et diminuer leur chute a base de derives de piperidino-pyrimidine
US6465514B1 (en) 1986-12-29 2002-10-15 Kenneth M. Hallam Methods and compositions for the promotion of hair growth
US4828837A (en) 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
US5030442A (en) 1987-03-30 1991-07-09 Liposome Technology, Inc. Non-crystalline minoxidil composition
US5225189A (en) 1988-02-18 1993-07-06 The Upjohn Company Minoxidil gel
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5407944A (en) 1993-02-19 1995-04-18 Goldman; Boris E. Compositions and methods for promoting hair growth
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US5620980A (en) 1995-02-22 1997-04-15 Macrochem Corporation Method for treating hair loss
US5834014A (en) 1995-10-06 1998-11-10 The Regents Of The University Of Michigan Stimulation of hair follicles
DE69823852T2 (de) * 1997-02-04 2005-05-19 Johnstone, Murray A., Seattle Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
AUPP310798A0 (en) 1998-04-22 1998-05-14 Soltec Research Pty Ltd Vehicle system for a composition comprising a piperidinopyrimidine derivative
US7534773B1 (en) 1999-02-26 2009-05-19 The University Of British Columbia TRPM-2 antisense therapy
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6495498B2 (en) 1999-05-27 2002-12-17 Johnson & Johnson Consumer Companies, Inc. Detergent compositions with enhanced depositing, conditioning and softness capabilities
CA2309373A1 (en) 1999-05-27 2000-11-27 Johnson & Johnson Consumer Companies, Inc. Novel topical formulations
US6596266B2 (en) 2000-02-18 2003-07-22 Natural Science, Inc. Compositions containing minoxidil and saw palmetto for treating baldness
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US7442369B1 (en) 2000-08-09 2008-10-28 Mcneil Ab Compositions of minoxidil
JP2003155218A (ja) 2001-09-10 2003-05-27 Lion Corp 養育毛組成物
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US20040115234A1 (en) 2002-09-24 2004-06-17 Gewirtz Joan T. Cosmetic composition
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
TWI495471B (zh) 2003-08-12 2015-08-11 R Tech Ueno Ltd 促進毛髮生長之組成物及方法
GB0323908D0 (en) 2003-10-11 2003-11-12 Nupharm Lab Ltd Pharmaceutical foam formulation
EP1759702B1 (en) * 2004-05-26 2009-01-07 Arturo Jimenez Bayardo Method of preparing a latanoprost ophthalmic solution and solution thus produced
JP5780690B2 (ja) * 2005-08-25 2015-09-16 大正製薬株式会社 発毛剤組成物
US8147815B2 (en) 2005-12-16 2012-04-03 Celmatrix Corporation Topical administration carrier composition and therapeutic formulations comprising same
US20070160562A1 (en) 2006-01-06 2007-07-12 Brinkenhoff Michael C Delivery devices for hair-promoting cosmetic agent
US20150072963A1 (en) 2006-06-16 2015-03-12 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating hair growth
US7803357B2 (en) 2006-10-30 2010-09-28 John V Cappello Topical and transdermal treatments using urea formulation
US20080206156A1 (en) 2007-02-22 2008-08-28 Cronk Peter J Continuous spray scalp therapy and dispensing systems for same
EP2136787B1 (en) * 2007-03-22 2019-08-21 Berg LLC Topical formulations having enhanced bioavailability
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
US20080275118A1 (en) 2008-06-12 2008-11-06 Shaw Mari M Health and cosmetic composition and regime for stimulating hair growth and thickening on the head, including the scalp, eyelashes, and eyebrows, and which discourages hair loss
US20100204335A1 (en) 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
WO2010080915A1 (en) 2009-01-08 2010-07-15 Allergan, Inc. Compositions for enhancing nail growth
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
NZ628266A (en) 2009-11-09 2016-02-26 Allergan Inc Compositions and methods for stimulating hair growth
US8470833B2 (en) 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Hair growth and/or regrowth compositions
US20130030055A1 (en) 2010-03-24 2013-01-31 Allergan, Inc. Compositions and methods for treating hair loss, hair thinning, and hair color loss
ES2711274T3 (es) 2010-11-18 2019-04-30 Steven Yoelin Composiciones y métodos para el crecimiento del cabello
WO2013172838A1 (en) * 2012-05-17 2013-11-21 Steven Yoelin Compositions and methods for hair growth
JP6017455B2 (ja) * 2011-01-31 2016-11-02 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 毛髪成長を増強する方法
CA2856847A1 (en) 2011-11-25 2013-05-30 Adrianna Janell JACKSON Oil compositions and methods for increasing hair growth and/or preventing hair loss
WO2013106565A1 (en) 2012-01-10 2013-07-18 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide f2 alpha agonists
US20160136071A1 (en) 2013-06-12 2016-05-19 Edward Dunne Corboy, JR. Topical bimatoprost for promoting hair growth containing formulations
CN105658223B (zh) * 2014-05-23 2018-12-04 特里普海尔公司 用于减少脱发和/或增加毛发再生的组合物
US11696883B2 (en) * 2014-05-23 2023-07-11 Triple Hair Inc. Compositions for reducing hair loss and/or increasing hair regrowth
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
US9763359B2 (en) 2015-05-29 2017-09-12 Oracle International Corporation Heat pipe with near-azeotropic binary fluid
US20180200263A1 (en) * 2015-07-07 2018-07-19 Pearl E. Grimes TOPICAL TREATMENT REGIMENS CONTAINING A PROSTAGLANDIN F2a ANALOG AND A TOPICAL STEROID
US10561593B2 (en) 2015-12-28 2020-02-18 Johnson & Johnson Consumer Inc. Hair growth composition and method
WO2019034571A1 (de) 2017-08-17 2019-02-21 Sma Solar Technology Ag Verfahren und vorrichtung zur erfassung einer maximalen anlagenleistung einer photovoltaikanlage
ES2874152T3 (es) 2017-12-08 2021-11-04 Escilab Spolka Z Ograniczona Odpowiedzialnoscia Composición cosmética para promover el crecimiento del cabello
US10993944B2 (en) * 2019-08-07 2021-05-04 Aneira Pharma, Inc. Methods and compositions for the treatment of hair loss

Also Published As

Publication number Publication date
US20220296596A1 (en) 2022-09-22
US11918579B2 (en) 2024-03-05
US11541054B2 (en) 2023-01-03
US11166955B2 (en) 2021-11-09
US20210038683A1 (en) 2021-02-11
EP4331683A2 (en) 2024-03-06
US11253518B2 (en) 2022-02-22
US20210038601A1 (en) 2021-02-11
SI3886799T1 (sl) 2024-02-29
EP3886799A1 (en) 2021-10-06
HRP20231629T1 (hr) 2024-03-15
EP4331683A3 (en) 2024-08-07
US11696915B2 (en) 2023-07-11
HUE064366T2 (hu) 2024-03-28
MX2024005310A (es) 2024-05-17
US10993944B2 (en) 2021-05-04
US20220288090A1 (en) 2022-09-15
ES2966317T3 (es) 2024-04-19
PT3886799T (pt) 2023-12-22
BR112022000229A2 (pt) 2022-02-22
AU2020324403A1 (en) 2021-12-23
US20220288073A1 (en) 2022-09-15
PL3886799T3 (pl) 2024-03-18
JP2022543532A (ja) 2022-10-13
MX2021014220A (es) 2022-04-06
TW202220665A (zh) 2022-06-01
US11369610B2 (en) 2022-06-28
WO2021026084A1 (en) 2021-02-11
RS64965B1 (sr) 2024-01-31
US20220023298A1 (en) 2022-01-27
US10987355B2 (en) 2021-04-27
IL289687A (en) 2022-03-01
LT3886799T (lt) 2023-12-27
FI3886799T3 (fi) 2023-12-13
ECSP22001774A (es) 2022-02-25
US20210236491A1 (en) 2021-08-05
US11541053B2 (en) 2023-01-03
US20210038600A1 (en) 2021-02-11
KR20220044248A (ko) 2022-04-07
CL2022000067A1 (es) 2022-08-19
SA522431538B1 (ar) 2024-05-17
EP3886799B1 (en) 2023-11-15
US20210236490A1 (en) 2021-08-05
US20240197734A1 (en) 2024-06-20
MD3886799T2 (ro) 2024-01-31
CN114007634A (zh) 2022-02-01
CA3140841A1 (en) 2021-02-11
CO2022000214A2 (es) 2022-01-17
US20220062283A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
DK3600270T3 (da) Forbindelser og sammensætninger til behandling af hæmatologiske lidelser
DK3402499T3 (da) Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes
DK3439635T3 (da) Formuleringer til behandling af fast tumor
DK3326641T3 (da) Rna-holdig sammensætning til behandling af tumorsygdomme
DK3509581T3 (da) Formuleringer af (r)-2-amino-3-phenylpropylcarbamat
DK3081263T3 (da) Sammensætninger og redskaber til behandling af glaukom
DK3924443T3 (da) Compositions
DK3573620T3 (da) Sammensætninger til behandling af hypertension
DK3478713T3 (da) Sammensætninger til behandling af amyloidose
DK3638293T5 (da) Sammensætninger til behandling af cancer
DK3807316T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer
DK3445849T3 (da) Fremgangsmåder og sammensætninger til at forbedre de anti-inflammatoriske virkninger af Interleukin-10
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi
DK3403674T3 (da) Farmaceutiske sammensætninger til behandling af smerte
DK3678644T3 (da) Formuleringer af copanlisib
DK3886799T3 (da) Sammensætninger til behandlingen af hårtab
DK3840596T3 (da) Sammensætning
DK3743064T3 (da) Behandling af proteinuri
DK3574912T3 (da) Sammensætning til behandling af diabetisk sygdom
DK3436073T3 (da) Sammensætning omfattende PIC til behandling af cancer
DK3886857T3 (da) Montelukast til behandlingen af erosiv håndosteoartritis
DK3620452T3 (da) Fremgangsmåde til fremstilling af lenvatinib
DK3490970T3 (da) Sammensætninger til behandling af lungefibrose
DK3548006T3 (da) Sammensætning til behandling af tarmforandringer
DK3763212T3 (da) Artropoda-afvisende sammensætning